腾景科技(688195.SH):拟设立控股子公司开展“合肥功能晶体材料与器件建设项目”
格隆汇5月29日丨腾景科技(688195.SH)公布,为加强公司在功能晶体材料和功能晶体器件方面的研发和制造能力,丰富公司晶体及器件的产品品类,拓展激光和生物医疗的光学业务,公司拟与安徽晶湖创业投资合伙企业共同出资3000万元设立控股子公司“合肥众波功能材料有限公司”,并由控股子公司与合肥高新技术产业开发区管理委员会投资招商中心签署《功能晶体材料与器件建设项目投资合作协议书》及《功能晶体材料与器件建设项目投资合作补充协议书》,开展“合肥功能晶体材料与器件建设项目”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.